retatrutide triple agonist glp-1 gip glucagon phase 2 obesity From to Metabolic Health: Why Is a Game-Changer Targeting GLP-1, GIP & GCG
Description
It doesnt impair function
PMID: 40010803
A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control
Together, GLP-1s are on pace to exceed $30 billion annualized
doi: 10.1111/all.14879 101 HurJKangJYKimYKLeeSYLeeHY
